Deciphera Pharmaceuticals is a biopharmaceutical company focused on discovering, developing, and commercializing medicines to improve the lives of people with cancer. Using its proprietary switch-control kinase inhibitor platform and capabilities in kinase biology, Co. designs kinase inhibitors to target the switch pocket region of the kinase with the goal of developing medicines. QINLOCK, Co.'s switch-control kinase inhibitor, was developed using Co.'s proprietary drug discovery platform and developed for the treatment of fourth-line gastrointestinal stromal tumor. Co. has developed a pipeline of drug candidates, including vimseltinib and DCC-3116. The DCPH average annual return since 2017 is shown above.
The Average Annual Return on the DCPH average annual return since 2017 page and across the coverage universe of our site,
is a measure of the annualized return over the past ten years (or specified start date) for a given investment
(up to the end of prior trading session recorded). Arguably, choosing ten years for a measurement
period is on the one hand completely arbitrary, but on the other hand provides a sufficiently long window
to capture long-term trends.
Thus, researching Average Annual Returns is good practice for investors — whether DCPH average annual return since 2017 or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's annualized return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the DCPH average annual return calculation with any dividends reinvested as applicable (on ex-dates).
|